OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2020.11497 OL-0-0-11497 Articles Myeloid-derived suppressor cells infiltration in non-small-cell lung cancer tumor and MAGE-A4 and NY-ESO-1 expression HouZhenbo 1 LiangXiao 2 WangXinmei 1 ZhouZiqiang 1 ShiGuilan 3 4 Department of Pathology, Zibo Central Hospital, Zibo, Shandong 255000, P.R. China Department of Thoracic Surgery, Zibo Central Hospital, Zibo, Shandong 255000, P.R. China Department of Immunology, School of Nursing, Zibo Vocational Institute, Zibo, Shandong 255314, P.R. China Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, VA 23508, USA Correspondence to: Dr Guilan Shi, Department of Immunology, School of Nursing, Zibo Vocational Institute, 30 Shiji Road, Zibo, Shandong 255314, P.R. China, E-mail: shiguilan126@126.com 06 2020 31 03 2020 19 6 3982 3992 28052019 14012020 Copyright: © Hou et al. 2020 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Cancer/testis antigens melanoma-associated antigen 4 (MAGE-A4) and New York esophageal squamous cell carcinoma-1 (NY-ESO-1) are of clinical interest as biomarkers and present valuable targets for immunotherapy; however, they are poor prognostic markers in non-small cell lung cancer (NSCLC). In addition, myeloid derived suppressor cells (MDSCs) are recognized as a key element in tumor escape and progression. The aim of the present study was to investigate the diagnostic and prognostic value of MAGE-A4 and NY-ESO-1, and their association with MDSCs in NSCLC samples. The expression levels of MAGE-A4 and NY-ESO-1, and the infiltration of MDSCs (CD33+), were analyzed by immunohistochemistry of 67 tissue samples from patients with NSCLC. Overall, 58.33% of the NSCLC squamous cell carcinoma tissues and 94.7% of adenocarcinoma tissues were positive for MAGE-A4. NY-ESO-1 expression was observed in 52.78% of the squamous cell carcinoma tissues and 80% of the adenocarcinoma tissues. In primary adenocarcinoma tumor tissues, MAGE-A4 and NY-ESO-1 demonstrated a higher intensity of expression compared with the squamous cell carcinoma tissues. A total of 33 (91.7%) squamous cell carcinoma and 19 (95.0%) adenocarcinoma specimens were positive for CD33. The expression of MAGE-A4 and NY-ESO-1 antigens and infiltration of MDSCs was associated with poor prognosis of patients with NSCLC. Further studies investigating the association between these findings and underlying molecular mechanisms are required.

 non-small cell lung cancer melanoma-associated antigen 4 New York esophageal squamous cell carcinoma-1 myeloid derived suppressor cells Introduction

As the leading cause of cancer-associated death worldwide in 2018, lung cancer causes significant challenges for cancer researchers (1). Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for ~85% of all cases (2). The long-term prognosis of patients with lung cancer is poor and the overall 5-year survival rate has been reported to be as low as 18% in USA according to the American Cancer Society (3).

Recent evidence of the clinical efficacy of immunotherapeutic approaches, including chimeric antigen receptor, T-cell therapy, immune checkpoint blockade and vaccine therapy (4–6), for lung cancer suggests that immunotherapy will become the next major therapeutic advance for this disease. Vaccines include antigen specific therapies, which induce specific antitumor immunity against relevant tumor-associated antigens. The cancer/testis (CT) family of antigens, including melanoma-associated antigen 4 (MAGE-A4) and New York esophageal squamous cell carcinoma-1 (NY-ESO-1), has been a focus of previous studies (7,8) due to their potential as immunotherapeutic targets (9,10). Furthermore, experimental studies have shown the ability of CT antigens to elicit a specific cellular response, including cytotoxic T lymphocytes (CTLs), and humoral immune responses (9,11–14). The presence of high numbers of CTLs in the tumors of patients with NSCLC is associated with enhanced survival (15–17); however, contrasting results demonstrated that high expressions of CT antigens were associated with poor survival in patients with lung cancer (18,19). A possible reason for this may be the accumulation of myeloid derived suppressor cells (MDSCs) in peripheral lymphoid organs and tumor tissues (20,21).

MDSCs represent a heterogeneous population of immature myeloid cells that can strongly inhibit anti-tumor activities of T and NK cells and stimulate regulatory T cells (Treg), leading to tumor progression. Furthermore, MDSCs can contribute to patient resistance to immunotherapy (22,23). Several studies have examined the association between the MAGE-A4 and NY-ESO-1 expression levels and survival (18,24–29), as well as the association between the MDSCs infiltrated in the tumor microenvironment and the survival of patients with different types of lung cancer (30–33). However, the prognosis of the association between the MAGE-A4 or NY-ESO-1 and MDSCs has yet to be confirmed. The present study aimed to disclose the association between the expression levels of MAGE-A4 or NY-ESO-1 and MDSCs infiltration in patients with NSCLC.

 Materials and methods <sec> <title>NSCLC tissue selection

A total of 67 cases of NSCLC were retrieved from the archives of the Zibo Central Hospital between February 2010 and March 2015. The patients' records included clinical data, preoperative examination results, details of surgical operations, histopathological findings and Tumor Node Metastasis (TNM) staging (34). The preoperative assessments included magnetic resonance imaging of the brain, bronchoscopy and bone scintigraphy. None of the patients underwent radiation or chemotherapy before surgery. The present study was approved by The Ethics Committee of Zibo Central Hospital (Zibo, China) in accordance with the Declaration of Helsinki and all procedures were approved by the Institutional Review Board of Zibo Central Hospital (Zibo, China). Tissue samples, including lung cancer specimens and normal tissues adjacent to tumor, were collected after informed consent was provided by all patients. The histopathological subtype, stage and grade of the tumors were determined by four pathologists according to the guidelines of the World Health Organization Classification of Lung Tumors (The 2015 World Health Organization Classification of Lung Tumors) (35). For survival analysis, follow-up was also performed. Patient survival was calculated as the time between surgery and mortality. Patients who were still alive at the time of data collection were censored in the statistical analysis (Table I).

 Immunohistochemistry (IHC)

IHC was performed according to the following protocol. Briefly, 0.9% saline washed-surgical resections were cut into 4 mm thickness and fixed with 10% formaldehyde overnight at room temperature. After dehydration with increasing concentration of ethanol (50, 70, 90 and 100%) and cleaning with xylene, tissues were embedded with paraffin (36). Consecutive sections from paraffin-embedded tissue blocks were cut into 4-µm sections, deparaffinized and rehydrated with xylene and descending ethanol (100, 90, 70 and 50%). Endogenous peroxidase activity was blocked by a 10-min incubation with 0.3% hydrogen peroxide in methanol at room temperature. Epitope retrieval was performed using 1 mM EDTA buffer (pH 8.0) in a microwave for 15 min, followed by cooling for 20 min at room temperature. Sections were washed with PBST and blocked with 10% normal goat serum (cat. no. G9023; Sigma-Aldrich; Merck KGaA) for 30 min at room temperature. The expression of NY-ESO-1, MAGE-A4 and CD33 in lung cancer and normal tissues was detected by incubation with primary monoclonal antibodies against NY-ESO-1 (1:200; cat. no. 35–6200; Thermo Fisher Scientific, Inc.), MAGE-A4 (1:150; cat. no. ab139297; Abcam) and CD33 (1:100; cat. no. 303402; BioLegend, Inc.) at 4°C overnight. Sections were washed three times with PBST and were incubated with goat anti-mouse secondary antibody, HRP (1:2,000; cat. no. 62-6520; Thermo Fisher Scientific, Inc.) for 1 h at room temperature. Sections were washed three times with PBST and were incubated with 5% 3,3-diaminobenzidine for 10 min at room temperature until brown colors developed. Slides were counterstained with hematoxylin and mounted on glass coverslips. Slides were viewed under bright field using an upright microscope BX63 (Olympus Corporation), and representative areas were photographed using a CCD camera and processed using Olympus Image Analysis software (Olympus Stream 1.9; Olympus Corporation). The levels of MAGE-A4, NY-ESO-1 and CD33 expression were determined using a semi-quantitative four-grade scoring system (+, 5–25%; ++, 25–49%; +++, 50–75%; ++++, >75% of cells stained). Focal staining of single cells or small clusters (<5% total) was considered as negative staining. There was no significant difference between the expression levels of MAGE-A4, NY-ESO-1 and CD33 in patients with NSCLC using the four-grade scoring system. Patients were therefore classified into positive and negative groups. The positive group included tissues stained from + to ++++. Individual core counts from five replicates were available for most cases.

 Statistical analysis

IHC data was evaluated using a χ2 test. Pearson's correlation analysis was used to confirm the association between variables. The Kaplan-Meier method was used to estimate the probability of survival and survival differences were analyzed using a log-rank test. The receiver operating characteristic (ROC) curve was used to determine the optimal cut-off values for the sensitivity and specificity of both CT antigens and CD33 in NSCLC prognosis. P<0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed using SPSS version 10.0 software (SPSS, Inc.).

 Results <sec> <title>Clinicopathological parameters

The clinicopathological characteristics of the 67 patients with lung cancer included in this study are summarized in Table I. The average age of patients was 66 years (age range, 38–79 years). Patients included 51 men (76.12%) and 16 women (23.88%). Pathologically, 36 (53.73%), 20 (29.85%), 11 (16.42%) patients were diagnosed with squamous cell carcinoma (SCC), adenocarcinoma, and other pathologies than adenocarcinoma or SCC, including composite large-cell neuroendocrine carcinoma and squamous cell carcinoma, composite large-cell carcinoma and squamous cell carcinoma, composite clear cell carcinoma and squamous cell carcinoma, large cell (undifferentiated) carcinoma and adenosquamous carcinoma. The pathological stages were at Ia, Ib, IIa, IIb and IIIa in 11, 38, 12, 5 and 1 patients, respectively. Clinical follow-up was available for all cases. The median follow-up period was 48 months (range, 6–89 months).

 MAGE-A4, NY-ESO-1 and CD33 are upregulated in NSCLC tissues according to IHC

Expression levels of MAGE-A4 and NY-ESO-1 in NSCLC specimens (specially focusing on squamous cell carcinoma and adenocarcinoma) were analyzed using IHC staining. To evaluate the immune suppressor cells infiltrating the tumor microenvironment, CD33 was detected using IHC. Furthermore, no staining of normal tissue adjacent to the positively stained tumors was detected (Fig. 1). The semi-quantitative results of immunohistochemical staining with MAGE-A4, NY-ESO-1 and CD33 monoclonal antibodies are shown in Tables II–V.

 In terms of MAGE-A4, 71.4% of NSCLC tissues demonstrated positive staining

According to the histological types, the positive expression rates of MAGE-A4 in patients with squamous cell carcinoma and adenocarcinoma were 58.33 and 94.7% (P=0.004), respectively (Table II). Regarding NY-ESO-1, NSCLC tissues demonstrated relatively low positive staining (62.5%). Considering the histological types, the positive expression rates of NY-ESO-1 were 52.78% in squamous cell carcinoma samples and 80% in adenocarcinoma samples (P=0.04; Table II). The MAGE-A4 and NY-ESO-1 double expression rate was 70% in adenocarcinoma tissues, which was significantly higher compared with the expression rate in squamous carcinoma (38.89%; P=0.026; Table III). In each histological type, tumor differentiation was associated with the expression of MAGE-A4 and NY-ESO-1 antigens. As shown in Table II, 92.90% of NSCLC tissues were positive for CD33 expression. The positive expression rates of CD33 in squamous cell carcinoma and adenocarcinoma were 91.7 and 95.0% (P=0.6; Table II).

According to sex, the MAGE-A4-positive expression rate was significantly higher in women (84.6%) compared with men (65.1%; P<0.01; Table IV). NY-ESO-1 also demonstrated a greater expression in females compared with males (69.2 vs. 53.5%; P<0.05; Table IV). As for CD33, there was a similar expression rate in women (84.6%) and men (90.1%). The expression of both CT antigens and CD33 in NSCLCs was not correlated with patients age, TNM-pT and stage (data not shown).

 Association between MDSC infiltration and combined patterns of CT antigens expression

A total of four combined expressions of MAGE-A4 and NY-ESO-1 were evaluated to determine the association with MDSC infiltration (Table III). Combined positive expression for CD33, NY-ESO-1 and MAGE-A4 was significantly higher in adenocarcinoma tissues (55.00%) compared with squamous carcinoma tissues (36.11%; P=0.171). The double expression rates of CD33/MAGE-A4, CD33/NY-ESO-1 and MAGE-A4/NY-ESO-1 were higher in squamous cell carcinoma compared with adenocarcinoma tissues (Table III). A χ2 test was used to analyze the association between MAGE-A4 and NY-ESO-1 expression and between CT antigens and CD33 expression. The group with positive MAGE-A4 or NY-ESO-1 staining demonstrated a higher number of infiltrating MDSCs compared with the groups with negative MAGE-A4 or NY-ESO-1 expression (P<0.005; Table V). In addition, the expression levels of both CT antigens in NSCLC were correlated (Pearson's r=0.411; P=0.002; Table V).

The association between the CT antigens expression and CD33 was analyzed using a χ2 test. There was no significant association between CT antigens expression and MDSC infiltration, although CD33 was expressed more frequently in CT antigens patients with positive expression compared with patients with negative expression (Tables III and V).

 Prognostic value of MAGE-A4, NY-ESO-1 and CD33 expression

By using log-rank test, CD33 expression was significantly associated with survival rate (P=0.03; Fig. 2A). MAGE-A4 and NY-ESO-1 expression levels were identified to be significantly associated with prognosis in terms of survival rate (Fig. 2B and C; P=0.005 and P=0.001, respectively). Subsequently, tissues were classified based on pathological type to examine the prognostic value of CT antigens and MDSC infiltration. By contrast, no association was identified between histology type and survival rate in patients positive in both CT antigen expression and CD33 expression (Fig. 2D-F), although there was a higher expression of CT antigens in adenocarcinoma compared with patients with squamous cell cancer (Table II; MAGE-A4, 58.33% positive expression in squamous cell cancer and 94.7% in adenocarcinoma; NY-ESO-1, 52.78% positive expression in squamous cell cancer and 80% in adenocarcinoma). These results demonstrated that a poor prognosis was associated with positive CT antigen and CD33 expression in patients with squamous cell cancer and adenocarcinoma.

 Prognostic value of MDSCs in patients with MAGE-A4 or NY-ESO-1-positive expression

In order to evaluate the association between MDSCs and prognosis in patients positively expressing CT antigens, the associated between the CT antigens expression and the infiltration of MDSCs into the tumor site was analyzed (Fig. 3). In tissues positive for MAGE-A4, there was a significant difference between CD33-positive expression and CD33-negative expression in terms of survival rate (P=0.013; Fig. 3A). Compared with CD33-positive expression, the survival rate of patients with negative CD33-negative staining was improved, whereas there was no significant difference survival rate between in NY-ESO-1-positive and NY-ESO-1-negative cases (P=0.054; Fig. 3B). For further analysis of the sensitivity and specificity of both CT antigens and CD33 in NSCLC prognosis, a receiver operating characteristic (ROC) curve was used to analyze the present results. The area under the ROC curve was 0.60, 0.626 and 0.721 for expression of MAGE-A4, NY-ESO-1 and CD33, respectively (Fig. 4).

 Discussion

The evidence of clinical efficacy for immunotherapeutic approaches for lung cancer suggests that immunotherapy will become the next major therapeutic advance for this disease (5,37,38). NSCLC has historically been considered as a nonimmunogenic disease (2). Previous data has shown that much of this lack of immune responsiveness to lung cancer is due to high expression of CT antigens, which are expressed in the normal testis and placenta, but may also be expressed in tumor tissues (39–44). Thus, it is essential to determine the association between expression levels of CT antigens and prognosis of patients with lung cancer. In the present study, the expression of MAGE-A4 and NY-ESO-1 was analyzed by immunohistochemistry of 67 tissue samples from patients with NSCLC, and the survival of these patients was assessed. Patients with high expression of both CT antigens exhibited a poor prognosis, which was consistent with previous studies (19,43,45). This may be due to the immunosuppressive microenvironment of the tumor (19). Regardless of the fact that MAGE and NY-ESO-1 can trigger a strong immune reaction by stimulating lymphocyte migration into the tumor microenvironment, these T cells do not readily translate to tumor cell killing in vivo (9,19).

Tumor infiltrating lymphocytes are important factors in the antitumor immune response, which are associated with cancer incidence, tumor growth, response to therapy and the prognosis of the disease (46). Intensive infiltration of CTLs into the tumor nest is associated with good patient prognosis in several tumor types (47–51). Tumor-specific CTLs recognizing MAGE-A4 and NY-ESO-1 have been reported and several CTL epitopes within MAGE and NY-ESO-1 proteins have been identified (9,52,53). However, the present study did demonstrate an association between high expression of MAGE-A4 or NY-ESO-1 and a poor prognosis in patients with NSCLC. One possible explanation for this apparent contradiction may be some association with suppressive immune cells, including MDSCs (54,55).

The immune system plays a paradoxical role in the response to tumors by either preventing tumor growth or by permitting tumor escape and stimulating tumor development (7). MDSCs are a group of immature immune cells, which normally are not found in the circulation but accumulate in the blood and tumor of patients with cancer (56,57). MDSCs are involved in immune evasion of tumors (21). The importance of MDSCs in cancer-related immunosuppression is evident by the inhibitory effect on T cell proliferation and function and the fact that removal of MDSCs can restore T cell effector function (58,59). Until now, the role of MDSCs in the expression of MAGE-A4 or NY-ESO-1 has remained elusive. Thus, the present study aimed to address the integrated relationship among the expression level of MAGE-A4 and NY-ESO-1, overall survival and infiltration of MDSCs into the tumor site in patients with NSCLC.

The positive frequency of MAGE-A4, NY-ESO-1 and CD33 expression in NSCLC in present study was higher than that in previous studies (28,60). Notably, MAGE-A4 and NY-ESO-1 were more highly expressed in adenocarcinoma compared with in squamous cell carcinoma tissues. These results are inconsistent with previous research (61). Intra-tumoral heterogeneity may partly explain the different extent to which certain CT antigens were re-expressed in tumors in the present study compared with previous work (62,63). In addition, discrepancies between RNA and protein expression levels are not uncommon and may contribute to the variety of expression levels reported (64); however, the association between CT antigen expression and disease development and tumor malignancy remains unclear, including NSCLC (65–69). It has been hypothesized that there is no association between the expression of CT antigens and sex (70,71); however, the present study demonstrated that a higher proportion of NSCLC tissue samples from female patients stained positive for CT antigens compared with samples from males. The genes that encode MAGE-A4 and NY-ESO-1 map to the X chromosome and are referred to as CT-X genes (62,72). This may be indicative of the association of CT antigens with the female sex and could be associated with a dominance of female patients within adenocarcinoma group showing a higher expression of CT antigens (73–76). Regarding cancer stage, CT antigen expression patterns are associated with disease stage and no expression of CT antigens has been observed in benign tissues (64). However, the present study demonstrated a weak association between tumor stage and the expression of both CT. The possibility may be not at advanced stage with these observed samples.

As for survival, the high expression of MAGE-A4 and NY-ESO-1 was a prognostic marker for a less favorable prognosis in patients with NSCLC. These results were indicative of a possible role of MAGE-A4 and NY-ESO-1 in determining greater malignant potential in types of lung cancer, although the underlying mechanism of function of these CT antigens in tumor biology has not been fully elucidated. The poor prognostic association of MAGE-A4 and NY-ESO-1 in lung cancer suggests that the development of therapy targeting both of these CT antigens may be a potential novel treatment for patients with NSCLC.

There was no clear association between MDSCs infiltration and MAGE-A4 or NY-ESO-1-positive expression in the present study and the results were inconsistent with our previous animal experiment (77). This may be explained by variation among species, different immunohistochemical sensitive antibodies depending on laboratory conditions and tumor cell heterogeneity. Previously, ROC curve analysis was used to assess diagnostic tests, which could also be used to assess predictive models (78–82). Limited by sample size, the ROC curves in the present study were based on patient survival without a series of cut-off points. The results indicated that MAGE-A4, NY-ESO-1 and CD33 expression were better markers of the prognosis of patients with NSCLC.

When analyzing the prognosis in different pathological types, squamous cell cancer and adenocarcinoma, there was no significant difference in survival between these two pathological types; however, MAGE-A4 and NY-ESO-1 expression had a significant difference in expression between squamous cell cancer and adenocarcinoma. A possible reason for this may be that the similar expression rate of CD33 in squamous cell cancer and adenocarcinoma (83). The present results indicated that higher CD33 expression levels were correlated with poorer prognosis. Given MDSC inhibition of T cells activation in a nonspecific or antigen-specific manner (22,23), altering the dendritic cell peptide presenting ability of the major histocompatibility complex class I molecules on tumor cells (24,25), the functional analysis of CD8+ T cells might help understanding how MDSC could undermine the activity of CD8+ T cells within tumor nests. (22,84).

The limitations of the present study should be noted. The sample size was small, as all data were obtained from 67 cases. Due to the heterogeneity in patients with lung cancer, survival may be affected by histology and staging. In present study, the survival of patients with squamous cell carcinoma and adenocarcinoma was analyzed. In our previous experiment, we found that tumor infiltrating MDSCs enhanced the expression of MAGE-A4 in an animal model (77). Thus, the purpose of present study was to investigate the association between the expression levels of MAGE-A4 or NY-ESO-1 and MDSCs infiltration in patients with NSCLC. Once there is positive or negative correlation between CT antigens expression and MDSCs the molecule and pathway which affects the protein expression should be investigated which may then be beneficial to cancer therapy. Given the immunogenicity of CT antigen and immune suppression of MDSC, CT antigen expression can be upregulated, which would induce anti-tumor immune response and MDSCs be downregulated, which would attenuate MDSCs-induced immunosuppression. However, the present study was limited by the sample size and no such correlation was observed, although there was a tendency to some degree between CT antigens expression and MDSC infiltrating in tumor microenvironment. In future research, considering that larger sample sizes produce more reliable results with greater precision and power (85–87), the study population should consist of long-surviving and short-surviving patients with NSCLC and the correlation between CT antigens expression and CTL infiltration or between CTL and MDSC infiltrations should be investigated.

In conclusion, the poor prognosis of patients with NSCLC with MAGE-A4 and NY-ESO-1 expressing tumors with high infiltrating MDSCs suggests that the spontaneous immune response is not sufficient against these antigens. The development of a combination therapy is required for patients with NSCLC with tumors expressing CT antigens, such as vaccinating with MAGE-A4 and NY-ESO-1 recombinant proteins or peptides. In addition, this combination therapy should combine with an inhibitor targeting CD33 to reduce the suppressive MDSCs.

 Acknowledgements

The authors would like to thank Dr Richard Heller (Frank Reidy Research Center for Bioelectrics, Old Dominion University) for his helpful and critical comments during the preparation of this manuscript.

 Funding

The present study was supported by the Shandong Province Higher Educational Science and Technology Program (grant no. J13LK58) and was supported in part by a Grant-in-Aid from the Zibo Vocational Institute (grant no. 2013VC01).

 Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

 Authors' contributions

GS was involved in the study design and data interpretation; drafting, revision and final approval of the manuscript. ZH performed the pathological evaluation of the specimens and participated in patients' follow-up. XL was responsible for the recruitment of the patients in the study and obtained the informed consent. XW and ZZ performed the immunohistochemistry staining. All authors had intellectual input into the study and read and approved the final manuscript.

 Ethics approval and consent to participate

The present study was approved by the Ethics Committee of Zibo Central Hospital (Zibo, China) in accordance with the Declaration of Helsinki, and all procedures were approved by the Institutional Review Board of Zibo Central Hospital (Zibo, China). Informed consent was obtained from all participants.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References BrayFFerlayJSoerjomataramISiegelRLTorreLAJemalAGlobal cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J Clin68394424201810.3322/caac.2149230207593 CarboneDPGandaraDRAntoniaSJZielinskiCPaz-AresLNon-small-cell lung cancer: Role of the immune system and potential for immunotherapyJ Thorac Oncol10974984201510.1097/JTO.000000000000055126134219 DeSantisCELinCCMariottoABSiegelRLSteinKDKramerJLAlteriRRobbinsASJemalACancer treatment and survivorship statistics, 2014CA Cancer J Clin64252271201410.3322/caac.2123524890451 ZeltsmanMDozierJMcGeeENgaiDAdusumilliPSCAR T-cell therapy for lung cancer and malignant pleural mesotheliomaTransl Res187110201710.1016/j.trsl.2017.04.00428502785 MayorMYangNStermanDJonesDRAdusumilliPSImmunotherapy for non-small cell lung cancer: Current concepts and clinical trialsEur J Cardiothorac Surg4913241333201610.1093/ejcts/ezv37126516195 ShroffGSde GrootPMPapadimitrakopoulouVATruongMTCarterBWTargeted therapy and immunotherapy in the treatment of non-small cell lung cancerRadiol Clin North Am56485495201810.1016/j.rcl.2018.01.01229622080 GroeperCGambazziFZajacPBubendorfLAdaminaMRosenthalRZerkowskiHRHebererMSpagnoliGCCancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancerInt J Cancer120337343200710.1002/ijc.2230917066423 AdamsSGreederLReichEShaoYFosinaDHansonNTasselloJSinghBSpagnoliGCDemariaSJungbluthAAExpression of cancer testis antigens in human BRCA-associated breast cancers: Potential targets for immunoprevention?Cancer Immunol Immunother609991007201110.1007/s00262-011-1005-721465317 ScanlanMJGureAOJungbluthAAOldLJChenYTCancer/testis antigens: An expanding family of targets for cancer immunotherapyImmunol Rev1882232200210.1034/j.1600-065X.2002.18803.x12445278 StockertEJagerEChenYTScanlanMJGoutIKarbachJArandMKnuthAOldLJA survey of the humoral immune response of cancer patients to a panel of human tumor antigensJ Exp Med18713491354199810.1084/jem.187.8.13499547346 MahmoudAMCancer testis antigens as immunogenic and oncogenic targets in breast cancerImmunotherapy10769778201810.2217/imt-2017-017929926750 GjerstorffMFAndersenMHDitzelHJOncogenic cancer/testis antigens: Prime candidates for immunotherapyOncotarget61577215787201510.18632/oncotarget.469426158218 SilinaKZayakinPKalninaZIvanovaLMeistereIEndzeliņšEAbolsAStengrēvicsALejaMDucenaKSperm-associated antigens as targets for cancer immunotherapy: Expression pattern and humoral immune response in cancer patientsJ Immunother342844201110.1097/CJI.0b013e3181fb64fa21150711 CogdillAPFrederickDTCooperZAGarberHRFerroneCRFiedlerARosenbergLThayerSPWarshawALWargoJATargeting the MAGE A3 antigen in pancreatic cancerSurgery152(3 Suppl 1)S13S18201210.1016/j.surg.2012.05.03122770803 ChewVChenJLeeDLohELeeJLimKHWeberASlankamenacKPoonRTYangHChemokine-driven lymphocyte infiltration: An early intratumoural event determining long-term survival in resectable hepatocellular carcinomaGut61427438201210.1136/gutjnl-2011-30050921930732 BenchetritFGazagneAAdoteviOHaicheurNGodardBBadoualCFridmanWHTartourECytotoxic T lymphocytes: Role in immunosurveillance and in immunotherapyBull Cancer906776852003(In French)14609756 PlatsoucasCDFinckeJEPappasJJungWJHeckelMSchwartingRMagiraEMonosDFreedmanRSImmune responses to human tumors: Development of tumor vaccinesAnticancer Res2319691996200312894571 YakirevichESaboELavieOMazarebSSpagnoliGCResnickMBExpression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasmsClin Cancer Res964536460200314695148 YoshidaNAbeHOhkuriTWakitaDSatoMNoguchiDMiyamotoMMorikawaTKondoSIkedaHNishimuraTExpression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significanceInt J Oncol2810891098200616596224 YamauchiYSafiSBlattnerCRathinasamyAUmanskyLJuengerSWarthAEichhornMMuleyTHerthFJFCirculating and tumor myeloid-derived suppressor cells in resectable non-small cell lung cancerAm J Respir Crit Care Med198777787201810.1164/rccm.201708-1707OC29617574 OrtizMLLuLRamachandranIGabrilovichDIMyeloid-derived suppressor cells in the development of lung cancerCancer Immunol Res25058201410.1158/2326-6066.CIR-13-012924778162 SchreiberRDOldLJSmythMJCancer immunoediting: Integrating immunity's roles in cancer suppression and promotionScience33115651570201110.1126/science.120348621436444 HanahanDWeinbergRAHallmarks of cancer: The next generationCell144646674201110.1016/j.cell.2011.02.01321376230 ZhangYZhangYZhangLExpression of cancer-testis antigens in esophageal cancer and their progress in immunotherapyJ Cancer Res Clin Oncol145281291201910.1007/s00432-019-02840-330656409 BaranCAAgaimyAWehrhanFWeberMHilleVBrunnerKWickenhauserCSieboltsUNkenkeEKestingMRiesJMAGE-A expression in oral and laryngeal leukoplakia predicts malignant transformationMod Pathol3210681081201910.1038/s41379-019-0253-530936424 JinSCaoSLiJMengQWangCYaoLLangYCaoJShenJPanBCancer/testis antigens (CTAs) expression in resected lung cancerOnco Targets Ther1144914499201810.2147/OTT.S15949130122941 KakimotoTMatsumineAKageyamaSAsanumaKMatsubaraTNakamuraTIinoTIkedaHShikuHSudoAImmunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcomaOncol Lett1739373943201930881511 UedaSMiyaharaYNagataYSatoEShiraishiTHaradaNIkedaHShikuHKageyamaSNY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinomaOncotarget93599736011201810.18632/oncotarget.2632330542513 ZimmermannAKImigJKlarARennerCKorolDFinkDStadlmannSSingerGKnuthAMochHCaduffRExpression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomasVirchows Arch462565574201310.1007/s00428-013-1395-323529156 VetsikaEKKoinisFGioulbasaniMAggourakiDKoutoulakiASkalidakiEMavroudisDGeorgouliasVKotsakisAA circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patientsJ Immunol Res2014659294201410.1155/2014/65929425436215 LangSBruderekKKasparCHöingBKanaanODominasNHussainTDroegeFEythCHadaschikBBrandauSClinical relevance and suppressive capacity of human myeloid-derived suppressor cell subsetsClin Cancer Res2448344844201810.1158/1078-0432.CCR-17-372629914893 Grauers WiktorinHNilssonMSKiffinRSanderFELenoxBRydströmAHellstrandKMartnerAHistamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockadeCancer Immunol Immunother68163174201910.1007/s00262-018-2253-630315349 BarreraLMontes-ServinEHernandez-MartinezJMOrozco-MoralesMMontes-ServínEMichel-TelloDMorales-FloresRAFlores-EstradaDArrietaOLevels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancerCancer Immunol Immunother6713931406201810.1007/s00262-018-2196-y29974189 RuschVWCrowleyJGirouxDJGoldstrawPImJGTsuboiMTsuchiyaRVansteenkisteJInternational Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating InstitutionsThe IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancerJ Thorac Oncol2603612200710.1097/01.JTO.0000283003.42414.c817607115 TravisWDBrambillaENicholsonAGYatabeYAustinJHMBeasleyMBChirieacLRDacicSDuhigEFliederDBThe 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classificationJ Thorac Oncol1012431260201510.1097/JTO.000000000000063026291008 SchachtVKernJSBasics of immunohistochemistryJ Invest Dermatol13514201510.1038/jid.2014.54125666678 GrahJSamijaMJuretićASarcevićBSobatHImmunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: The relationship with clinical-pathological featuresColl Antropol32731736200818982744 HamiltonGRathBImmunotherapy for small cell lung cancer: Mechanisms of resistanceExpert Opin Biol Ther19423432201910.1080/14712598.2019.159215530855195 WeiXChenFXinKWangQYuLLiuBLiuQCancer-Testis antigen peptide vaccine for cancer immunotherapy: Progress and prospectsTransl Oncol12733738201910.1016/j.tranon.2019.02.00830877975 GrahJJKatalinicDJureticASantekFSamarzijaMClinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancerTumori1006068201410.1177/1430.1581724675493 SmithSMIwenofuOHNY-ESO-1: A promising cancer testis antigen for sarcoma immunotherapy and diagnosisChin Clin Oncol744201810.21037/cco.2018.08.1130173534 SuCXuYLiXRenSZhaoCHouLYeZZhouCPredictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancerInt J Clin Exp Pathol855095518201526191258 JohnTStarmansMHChenYTRussellPABarnettSAWhiteSCMitchellPLWalkiewiczMAzadALambinPThe role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancerPLoS One8e67876201310.1371/journal.pone.006787623935846 OhueYKuroseKKarasakiTIsobeMYamaokaTFutamiJIreiIMasudaTFukudaMKinoshitaASerum antibody against NY-ESO-1 and XAGE1 antigens potentially predicts clinical responses to anti-PD-1 therapy in non-small-cell lung cancerJ Thorac Oncol1420712083201910.1016/j.jtho.2019.08.00831449889 Giavina-BianchiMGiavina-BianchiPSottoMNMuzikanskyAKalilJFesta-NetoCDuncanLMIncreased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanomaJ Immunol Res2015761378201510.1155/2015/76137825954764 Nazemalhosseini-MojaradEMohammadpourSTorshizi EsafahaniAGharibELarkiPMoradiAAmin PorhoseingholiMAsadzade AghdaeiHKuppenPJKZaliMRIntratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic featuresJ Cell Physiol23447684777201910.1002/jcp.2727330370522 OstroumovDFekete-DrimuszNSaborowskiMKühnelFWollerNCD4 and CD8 T lymphocyte interplay in controlling tumor growthCell Mol Life Sci75689713201810.1007/s00018-017-2686-729032503 LiHvan der LeunAMYofeILublingYGelbard-SolodkinDvan AkkooiACJvan den BraberMRozemanEAHaanenJBAGBlankCUDysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanomaCell176775789.e718201910.1016/j.cell.2018.11.04330595452 PrallFDührkopTWeirichVOstwaldCLenzPNizzeHBartenMPrognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instabilityHum Pathol35808816200410.1016/j.humpath.2004.01.02215257543 KnockeSFleischmann-MundtBSaborowskiMMannsMPKühnelFWirthTCWollerNTailored tumor immunogenicity reveals regulation of CD4 and CD8 T cell responses against cancerCell Rep1722342246201610.1016/j.celrep.2016.10.08627880900 DeschoolmeesterVBaayMVan MarckEWeylerJVermeulenPLardonFVermorkenJBTumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patientsBMC Immunol1119201010.1186/1471-2172-11-1920385003 SimpsonAJCaballeroOLJungbluthAChenYTOldLJCancer/testis antigens, gametogenesis and cancerNat Rev Cancer5615625200510.1038/nrc166916034368 AtanackovicDArfstenJCaoYGnjaticSSchniedersFBartelsKSchillingGFaltzCWolschkeCDierlammJCancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantationBlood10911031112200710.1182/blood-2006-04-01448017023585 FengPHLeeKYChangYLChanYFKuoLWLinTYChungFTKuoCSYuCTLinSMCD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancerAm J Respir Criti Care Med18610251036201210.1164/rccm.201204-0636OC LiYDLamanoJBLamanoJBQuaggin-SmithJVeliceasaDKaurGBiyashevDUnruhDBlochOTumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancerCancer Immunol Immunother6815011513201910.1007/s00262-019-02384-y31489465 AlmandBClarkJINikitinaEvan BeynenJEnglishNRKnightSCCarboneDPGabrilovichDIIncreased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancerJ Immunol166678689200110.4049/jimmunol.166.1.67811123353 GabrilovichDINagarajSMyeloid-derived suppressor cells as regulators of the immune systemNat Rev Immunol9162174200910.1038/nri250619197294 MovahediKGuilliamsMVan den BosscheJVan den BerghRGysemansCBeschinADe BaetselierPVan GinderachterJAIdentification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activityBlood11142334244200810.1182/blood-2007-07-09922618272812 NagarajSGabrilovichDIMyeloid-derived suppressor cellsAdv Exp Med Biol601213223200710.1007/978-0-387-72005-0_2217713008 KimSHLeeSLeeCHLeeMKKimYDShinDHChoiKUKimJYParkDYSolMYExpression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltrationLung187401411200910.1007/s00408-009-9181-319795170 HaierJOwzcareckMGullerUSpagnoliGCBürgerHSenningerNKocherTExpression of MAGE-A cancer/testis antigens in esophageal squamous cell carcinomasAnticancer Res2622812287200616821603 Al-KhadairiGDecockJCancer testis antigens and immunotherapy: Where do we stand in the targeting of PRAME?Cancers (Basel)11E984201910.3390/cancers1107098431311081 SigalottiLFrattaECoralSTanzarellaSDanielliRColizziFFonsattiETraversariCAltomonteMMaioMIntratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2′-deoxycytidineCancer Res6491679171200410.1158/0008-5472.CAN-04-144215604288 SalmaninejadAZamaniMRPourvahediMGolchehreZHosseini BereshnehARezaeiNCancer/Testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancersImmunol Invest45619640201610.1080/08820139.2016.119724127603913 FrattaECoralSCovreAParisiGColizziFDanielliRNicolayHJSigalottiLMaioMThe biology of cancer testis antigens: putative function, regulation and therapeutic potentialMol Oncol5164182201110.1016/j.molonc.2011.02.00121376678 AlmstedtMBlagitko-DorfsNDuque-AfonsoJKarbachJPfeiferDJägerELübbertMThe DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cellsLeuk Res34899905201010.1016/j.leukres.2010.02.00420381863 SongXSongWWangYWangJLiYQianXPangXZhangYYinYMicroRNA-874 functions as a tumor suppressor by targeting cancer/testis antigen HCA587/MAGE-C2J Cancer7656663201610.7150/jca.1367427076846 ThomasRAl-KhadairiGRoelandsJHendrickxWDermimeSBedognettiDDecockJNY-ESO-1 based immunotherapy of cancer: Current perspectivesFront Immunol9947201810.3389/fimmu.2018.0094729770138 ChinnasamyNWargoJAYuZRaoMFrankelTLRileyJPHongJJParkhurstMRFeldmanSASchrumpDSA TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancerJ Immunol186685696201110.4049/jimmunol.100177521149604 PengJRChenHSMouDCCaoJCongXQinLLWeiLLengXSWangYChenWFExpression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parametersCancer Lett219223232200510.1016/j.canlet.2004.07.02815723723 NagorsenDScheibenbogenCMarincolaFMLetschAKeilholzUNatural T cell immunity against cancerClin Cancer Res942964303200314555498 ChenYTChiuRLeePBeneckDJinBOldLJChromosome X-encoded cancer/testis antigens show distinctive expression patterns in developing gonads and in testicular seminomaHum Reprod2632323243201110.1093/humrep/der33022016418 RiveraMPStoverDEGender and lung cancerClin Chest Med25391400200410.1016/j.ccm.2004.01.00615099898 Barrera-RodriguezRMorales-FuentesJLung cancer in womenLung Cancer (Auckl)37989201228210127 HsuLHChuNMLiuCCTsaiSYYouDLKoJSLuMCFengACSex-associated differences in non-small cell lung cancer in the new era: Is gender an independent prognostic factor?Lung Cancer66262267200910.1016/j.lungcan.2009.01.02019299032 SakuraiHAsamuraHGoyaTEguchiKNakanishiYSawabataNOkumuraMMiyaokaEFujiiYJapanese Joint Committee for Lung Cancer RegistrationSurvival differences by gender for resected non-small cell lung cancer: A retrospective analysis of 12,509 cases in a Japanese lung cancer registry studyJ Thorac Oncol515941601201010.1097/JTO.0b013e3181f1923b20736855 ShiGWangHZhuangXMyeloid-derived suppressor cells enhance the expression of melanoma-associated antigen A4 in a Lewis lung cancer murine modelOncol Lett11809816201610.3892/ol.2015.391826870289 PerkinsNJSchistermanEFThe inconsistency of ‘optimal’ cutpoints obtained using two criteria based on the receiver operating characteristic curveAm J Epidemiol163670675200610.1093/aje/kwj06316410346 Hajian-TilakiKReceiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluationCaspian J Intern Med4627635201324009950 ObuchowskiNABullenJAReceiver operating characteristic (ROC) curves: Review of methods with applications in diagnostic medicinePhys Med Biol6307TR01201810.1088/1361-6560/aab4b129512515 CarterJVPanJRaiSNGalandiukSROC-ing along: Evaluation and interpretation of receiver operating characteristic curvesSurgery15916381645201610.1016/j.surg.2015.12.02926962006 KamarudinANCoxTKolamunnage-DonaRTime-dependent ROC curve analysis in medical research: Current methods and applicationsBMC Med Res Methodol1753201710.1186/s12874-017-0332-628388943 ZhangGHuangHZhuYYuGGaoXXuYLiuCHouJZhangXA novel subset of B7-H3(+)CD14(+)HLA-DR(−/low) myeloid-derived suppressor cells are associated with progression of human NSCLCOncoimmunology4e977164201510.4161/2162402X.2014.97716425949876 MarvelDGabrilovichDIMyeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpectedJ Clin Invest12533563364201510.1172/JCI8000526168215 KaplanRMChambersDAGlasgowREBig data and large sample size: A cautionary note on the potential for biasClin Transl Sci7342346201410.1111/cts.1217825043853 AndersonSFKelleyKMaxwellSESample-size planning for more accurate statistical power: A method adjusting sample effect sizes for publication bias and uncertaintyPsychol Sci2815471562201710.1177/095679761772372428902575 BiauDJKerneisSPorcherRStatistics in brief: The importance of sample size in the planning and interpretation of medical researchClin Orthop Relat Res46622822288200810.1007/s11999-008-0346-918566874

Immunohistochemical findings for MAGE-A4, NY-ESO-1 and CD33 in non-small cell lung cancer tissues. Specimens from the normal lung were used as a negative control. Staining of the normal lung demonstrated no reactivity for (A) CD33, (B) MAGE-A4 and (C) NY-ESO-1. Expression of (D) CD33, (E) MAGE-A4 and (F) NY-ESO-1 in squamous cell carcinoma. Expression of (G) CD33, (H) MAGE-A4 and (I) NY-ESO-1 in adenocarcinoma. Magnification, ×100. MDSCs, myeloid derived suppressor cells; MAGE-A4, melanoma-associated antigen 4; NY-ESO-1, New York esophageal squamous cell carcinoma-1.

Survival analysis of patients with lung cancer. Patients with squamous cell cancer and adenocarcinoma were analyzed by Kaplan-Meier method. Pair-wise differences were analyzed using the log-rank test. (A) CD33 expression and survival rate. (B) MAGE-A4 expression and survival rate. (C) NY-ESO-1 expression and survival rate. (D) MAGE-A4-positive expression and survival rate for patients with SCC or adenocarcinoma. (E) NY-ESO-1-positive expression and survival rate for patients with SCC or adenocarcinoma. (F) CD33-positive expression and survival rate for patients with SCC or adenocarcinoma. SCC, squamous cell cancer; MAGE-A4, melanoma-associated antigen 4; NY-ESO-1, New York esophageal squamous cell carcinoma-1.

Survival analysis of patients with lung cancer with positive MAGE-A4 and NY-ESO staining based on positive or negative CD33 expression. Data were analyzed by Kaplan-Meier method. Pair-wise differences were analyzed using the log-rank test. (A) CD33 expression and survival rate for patients with positive expression of MAGE-A4. (B) CD33 expression and survival rate for patients with positive expression of NY-ESO-1. MAGE-A4, melanoma-associated antigen 4; NY-ESO-1, New York esophageal squamous cell carcinoma-1.

ROC curve of MAGE-A4, NY-ESO-1, CD33 expression and survival of patients with non-small cell lung cancer. The area under the curve for MAGE-A4, NY-ESO-1 and CD33 was 0.600, 0.626 and 0.721, respectively. ROC, receiver operating characteristic; MAGE-A4, melanoma-associated antigen 4; NY-ESO-1, New York esophageal squamous cell carcinoma-1.

Clinicopathological parameter of patients with primary non-small cell lung cancer.

Parameter n %
Total 67a
Age, years
  >60 51 76.12
  ≤60 16 23.88
  Median (range) 66 (38–79)
Sex
  Male 51 76.12
  Female 16 23.88
Histology
  Squamous cell carcinoma 36 53.73
  Adenocarcinoma 20 29.85
  Other 11 16.42
pT status
  pT1a 19 28.36
  pT1b 34 50.75
  pT2a 8 11.94
  pT2b 5 7.46
  pT3 1 1.49
  Unknown
pN status
  pN0 51 76.12
  pN1 16 23.88
Systemic metastasis (before operation)
  No metastasis 67 100
Stage
  Ia 11 16.42
  Ib 38 56.72
  IIa 12 17.91
  IIb 5 7.46
  IIIa 1 1.49
Grade
  Well-differentiated 8 11.94
  Moderately differentiated 13 19.40
  Poorly differentiated 46 68.66
  Unknown
Median follow-up (range), months 48 (6–89)

One case missed their follow-up.

MAGE-A4, NY-ESO-1 and CD33 expression intensity in non-small cell lung cancer specimens.

MAGE-A4 NY-ESO-1 CD33
Extent of staininga Extent of staininga Extent of staininga
Histology Total n (% positive) − + ++ +++ ++++ Total n (% positive) − + ++ +++ ++++ Total n (% positive) − + ++ +++ ++++
Squamous cell carcinoma 36 (58.33) 15 7 5 5 4 36 (52.78) 17 8 3 4 4 36 (91.70) 3 11 16 6 0
Adenocarcinoma 20 (94.70)a 1 3 1 6 9 20 (80.00)b 4 0 2 11 3 20 (95.00)c 1 1 8 7 3
Total n (% positive) 40 (71.40) 35 (62.50) 52 (92.90)

−, negative; +, 5–25%; ++, 25–49%; +++, 50–75%; ++++, >75% of the tumor cells stained.

P=0.004

P=0.04

P=0.6. MAGE-A4, melanoma-associated antigen 4; NY-ESO-1, New York esophageal squamous cell carcinoma-1.

Combined positive expression of cancer/testis antigens MAGE-A4 and NY-ESO-1 and CD33.

Histology n CD33/MAGE-A4/NY-ESO-1 n (%) CD33/MAGE-A4 n (%) CD33/NY-ESO-1 n (%) MAGE-A4/NY-ESO-1 n (%)
Squamous cell carcinoma 36 13 (36.11) 18 (50) 17 (47.22) 14 (38.89)
Adenocarcinoma 20 11 (55) 15 (75) 11 (55) 14 (70)
P-value 0.171 0.068 0.5778 0.026

MAGE-A4, melanoma-associated antigen 4; NY-ESO-1, New York esophageal squamous cell carcinoma-1.

CT antigens, CD33 expression and clinicopathologic parameters in NSCLC.

MAGE-A4 NY-ESO-1 CD33
Sex n Negative n (%) Positive n (%) Negative n (%) Positive n (%) Negative n (%) Positive n (%)
Male 43 15 (34.9) 28 (65.1) 20 (46.5) 23 (53.5) 4 (9.1) 39 (90.1)
Female 13 2 (15.4) 11 (84.6) 4 (30.8) 9 (69.2) 2 (15.4) 11 (84.6)
P-value <0.01 <0.05

MAGE-A4, melanoma-associated antigen 4; NY-ESO-1, New York esophageal squamous cell carcinoma-1.

Multiple expression of CT antigens and CD33 in NSCLCs.

MAGE-A4 (positive) NY-ESO-1 (positive) CD33 (positive) MAGE-A4 (positive)b NY-ESO-1 (positive)
Histology n CD33 (negative) n (%) CD33 (positive) n (%) n CD33 (negative) n (%) CD33 (positive) n (%) n MAGA- 4 (negative) n (%) NY-ESO-1 (negative) n (%) n NY-ESO-1 (negative) n (%) NY-ESO-1 (positive) n (%) n MAGE-A4 (negative) n (%) MAGE-A4 (positive) n (%)
Squamous cell carcinoma 21 3 (14.3) 18 (85.7)a 18 1 (5.6) 17 (94.4)a 33 15 (45.4) 16 (48.5) 21 7 (33.3) 14 (66.7) 18 4 (22.2) 14 (77.8)
Adenocarcinoma 18 3 (16.7) 15 (83.3)a 14 3 (21.4) 11 (78.6)a 17 1 (5.9) 6 (35) 18 1 (0.06) 17 (94.4) 14 0 14 (100)

P<0.005.

Pearson's, r=0.411, P=0.002. MAGE-A4, melanoma-associated antigen 4; NY-ESO-1, New York esophageal squamous cell carcinoma-1.